Evaluate observational and epidemiologic risk signals for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) in patients prescribed semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), or control agents. Model absolute incidence, population rates, and clinical warning benchmarks.
| Study / Regulatory Body | Cohort / Scope | Reported Signal | Status / Legal Note |
|---|---|---|---|
| JAMA Ophthalmology (July 2024) | 16,827 patients (Mass Eye and Ear retrospective cohort) | HR 4.28 (T2D) / HR 7.64 (Obesity) | First major peer-reviewed paper documenting nonarteritic anterior ischemic optic neuropathy correlation. |
| FDA FAERS Database | Post-marketing adverse event spontaneous reports | Signal under evaluation | Dozens of personal injury complaints cited failure to warn regarding irreversible vision loss. |
| European Medicines Agency (EMA) | PRAC safety assessment review | Ongoing monitoring | Requested cumulative review from manufacturers for semaglutide & liraglutide products. |
| Novo Nordisk Official Statement | Global clinical trial datasets (SUSTAIN, STEP) | No causal link proven | Maintains data insufficient to establish causality; NAION is rare background event in diabetics. |
Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) is colloquially known as an "eye stroke." It occurs when blood flow to the anterior portion of the optic nerve head is acutely interrupted, leading to painless, sudden, and often irreversible partial or total loss of vision in one eye.
Lawsuits filed in 2024-2025 across federal courts allege pharmaceutical manufacturers failed to provide adequate warnings on drug packaging and physician inserts regarding this potential optic neuropathy risk, despite emerging pharmacological and post-marketing surveillance signals.
While the JAMA Ophthalmology study noted elevated Hazard Ratios (HR 4.28 for diabetic patients, HR 7.64 for weight-management cohorts receiving semaglutide compared to non-GLP-1 regimens), the absolute baseline incidence of NAION in the general population is very low (~2 to 10 cases per 100,000 patient-years).
Even with a 4-fold to 7-fold relative increase in susceptible subgroups with anatomical predispositions (such as a crowded optic disc), the absolute individual probability remains low, which is crucial for balanced clinical risk-benefit counseling.
No. This is a scientific and educational simulation tool that synthesizes published epidemiologic models, observational cohort metrics (specifically the Harvard / Mass Eye and Ear JAMA Ophthalmology 2024 paper), and baseline vascular risk variables. It is intended for healthcare researchers, clinicians, and informed patients to explore risk ratios and pharmacovigilance data.
Hypotheses under active investigation include GLP-1 receptor expression on optic nerve vasculature, rapid fluctuations in systemic perfusion pressure (specifically nocturnal dips), changes in vascular autoregulation, or microvascular osmotic stress triggered by steep reductions in HbA1c (similar to the transient worsening of diabetic retinopathy documented in the SUSTAIN-6 trials).
NNH represents the reciprocal of the absolute risk increase (ARI): NNH = 1 / (Cumulative Risk in Exposed - Cumulative Risk in Unexposed). An NNH of 140 means that across an estimated population with identical risk factors over a 3-year treatment window, approximately 140 patients would be treated before 1 additional NAION case is observed relative to controls.